China Compliance Scandal Leads To Cut In GSK CEO Bonus For 2013
This article was originally published in PharmAsia News
Executive Summary
Although GlaxoSmithKline increased revenues last year despite its compliance scandal in China, CEO Andrew Witty's take-home pay for the year has been docked by $409,000.